Axxam SpA is a member of an international consortium for the further development of a promising drug against neuropathic pain
Milan (Italy), 20 September 2018
Axxam is proud to announce its participation to a consortium of international partners, held by the Danish Hoba Therapeutics, for the further development of a promising drug against neuropathic pain. The consortium has received DKK 18.4M (≈USD3M) from the Innovation Fund Denmark, for the continued development of the drug candidate HB-086. Axxam will contribute to the success of the project with its experience in developing cell-based assays for the further evaluation of HB-086.
For more information please see the Press Release from the consortium below.